LNA SANTÉ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.24 EUR | +0.31% |
|
+0.21% | -4.28% |
| 03-28 | LNA Santé: 9% drop in annual RNPG | CF |
| 02-12 | LNA Santé: LNA Ensemble exceeds 10% of voting rights | CF |
Strengths
- Its low valuation, with P/E ratio at 8.29 and 9.12 for the ongoing fiscal year and 2024 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company does not generate enough profits, which is an alarming weak point.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.28% | 210M | C+ | ||
| -14.92% | 84.68B | B- | ||
| +13.30% | 81.12B | C+ | ||
| +10.92% | 29.4B | C+ | ||
| -12.71% | 16.73B | B | ||
| -3.06% | 16.36B | A- | ||
| -2.63% | 14.92B | A- | ||
| -31.75% | 11.77B | - | - | |
| -1.42% | 11.72B | A- | ||
| +27.44% | 11.71B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LNA Stock
- Ratings LNA Santé
